Teva has been asserting that Natco's drug isn't similar to Copaxone ever since MYL and Natco inked their collaboration in 2008 (#msg-29902618). The question is whether MYL has modified the drug to close the gap sufficiently. (If not, that's good news for MNTA, of course.)
MYL at JPM ridiculed Teva's PlosOne study, saying that what happens in healthy mice is not indicative of what happens in humans with MS and that the discrepancies cited in the paper have no clinical significance.
This sounds to be like an admission that there are indeed differences between the two products, although MYL claims that it has modified Natco's formulation.
News 
Market Data 
Discover 
